ReviewMedical mycology2019
A review of innate and adaptive immunity to coccidioidomycosis.
Review in Medical mycology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 49 citations in OpenAlex.
- Immunomodulation in the Treatment of Disseminated Coccidioidomycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Exhausted T cell phenotypes in disseminated coccidioidomycosis.JCI insight · 2026Article
- The Fungus Among Us: Latency, Reactivation, and the Expanding Clinical Spectrum of Coccidioidomycosis.Cureus · 2026Review
- Immune-Based Prevention and Therapy Against Coccidioidomycosis: Current and Emerging Approaches.Journal of fungi (Basel, Switzerland) · 2026Review
- Exhausted T cell phenotypes in disseminated coccidioidomycosis.medRxiv : the preprint server for health sciences · 2026Article
- Current perspectives of host-pathogen dynamics in coccidioidomycosis.Current opinion in microbiology · 2026Review
- Disseminated coccidioidomycosis with cutaneous, pulmonary and suspected CNS involvement in an elderly patient with Parkinson's disease.BMJ case reports · 2025Article
- Identification of Coccidioidomycosis Immunoreactive Peptides That Recall T-Cell Responses Indicating Past Exposure.The Journal of infectious diseases · 2025Article
- Overview of the Current Challenges in Pulmonary Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2024Review
- A microbial risk assessor's guide to Valley Fever (Coccidioides spp.): Case study and review of risk factors.The Science of the total environment · 2024Review
- Article
- The Host Response to Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2024Review
- Article
- Coccidioidomycosis Granulomas Informed by Other Diseases: Advancements, Gaps, and Challenges.Journal of fungi (Basel, Switzerland) · 2023Review
- Volatile Metabolites in Lavage Fluid Are Correlated with Cytokine Production in a Valley Fever Murine Model.Journal of fungi (Basel, Switzerland) · 2023Article
- Advocating for Coccidioidomycosis to Be a Reportable Disease Nationwide in the United States and Encouraging Disease Surveillance across North and South America.Journal of fungi (Basel, Switzerland) · 2023Article
- Granulomatous inflammation in inborn errors of immunity.Frontiers in pediatrics · 2023Review
- Prevalence of coccidioidomycosis in primary immunodeficiency: Data from the USIDNET registry.Clinical immunology (Orlando, Fla.) · 2022Article
- Vaccines to Prevent Coccidioidomycosis: A Gene-Deletion Mutant of Coccidioides Posadasii as a Viable Candidate for Human Trials.Journal of fungi (Basel, Switzerland) · 2022Review
- Key thermally dimorphic fungal pathogens: shaping host immunity.Open biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
Coccidioidomycosis is a human fungal disease cause by inhalation of aerosol spores produced by Coccidioides posadasii or Coccidioides immitis. This disease is a common cause of community-acquired pneumonia in the endemic areas of the Southwestern United States. It also can present as a life-threatening disease as the fungal cells disseminate to skin, bone, and central nervous system. The outcome of coccidioidomycosis is largely determined by the nature of host immune response to the infection. Escalation of symptomatic infections and increased cost of long-term antifungal treatment warrant a concerted effort to better understand the innate and adaptive immune responses and the genetics associated with coccidioidomycosis susceptibility. This knowledge can be harnessed for development of a human vaccine against Coccidioides and advance clinic management of this disease. This review discusses recently reported studies on innate and adaptive immunity to Coccidioides infection, Mendelian susceptibility to disseminated disease and progress toward a human vaccine against this formidable disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.